{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:30:03Z","timestamp":1777764603084,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018754","name":"An Roinn Sl\u00e1inte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004426","name":"Atlantic Philanthropies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ypmed.2021.106504","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T22:08:49Z","timestamp":1614722929000},"page":"106504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Aspirin prescribing for cardiovascular disease in middle-aged and older adults in Ireland: Findings from The Irish Longitudinal Study on Ageing"],"prefix":"10.1016","volume":"147","author":[{"given":"Frank","family":"Moriarty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose Anne","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2021.106504_bb0005","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","author":"Baigent","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.ypmed.2021.106504_bb0010","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ypmed.2021.106504_bb0015","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2021.106504_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2018.05.006","article-title":"Sl\u00e1intecare \u2013 a ten-year plan to achieve universal healthcare in Ireland","author":"Burke","year":"2018","journal-title":"Health Policy (New York)."},{"key":"10.1016\/j.ypmed.2021.106504_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018524","article-title":"Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease","volume":"8","author":"Byrne","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.ypmed.2021.106504_bb0030","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham heart study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ypmed.2021.106504_bb0035","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/M14-1281","article-title":"An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort","volume":"162","author":"DeFilippis","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ypmed.2021.106504_bb0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cgh.2012.08.034","article-title":"Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events","volume":"11","author":"Derogar","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ypmed.2021.106504_bb0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ejhpharm-2016-000967","article-title":"Deprescribing: a primary care perspective","volume":"24","author":"Duncan","year":"2017","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.ypmed.2021.106504_bb0050","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013404","article-title":"Low-dose aspirin for primary prevention of cardiovascular disease: use patterns and impact across race and ethnicity in the southern community cohort study","volume":"8","author":"Fernandez-Jimenez","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ypmed.2021.106504_bb0055","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/1741826710397850","article-title":"A national survey on aspirin patterns of use and persistence in community outpatients in Italy","volume":"18","author":"Filippi","year":"2011","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"10.1016\/j.ypmed.2021.106504_bb0060","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archinternmed.2011.32","article-title":"Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention","volume":"171","author":"Fried","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ypmed.2021.106504_bb0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5414\/CPP46072","article-title":"STOPP (screening tool of older Person's prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation","volume":"46","author":"Gallagher","year":"2008","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ypmed.2021.106504_bb0070","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2021.106504_bb0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/003335491513000614","article-title":"Preventive aspirin and other antiplatelet medication use among U.S. adults aged\u2265 40 years: data from the national health and nutrition examination survey, 2011\u20132012","volume":"130","author":"Gu","year":"2015","journal-title":"Public Health Rep."},{"key":"10.1016\/j.ypmed.2021.106504_bb0080","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(05)79284-9","article-title":"Hypertension optimal treatment (HOT) trial","volume":"352","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2021.106504_bb0085","series-title":"Primary Care Reimbursement Service Annual Report 2017. Dublin, Ireland","author":"Health Service Executive","year":"2017"},{"key":"10.1016\/j.ypmed.2021.106504_bb0090","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/EDE.0000000000000746","article-title":"Aspirin use and mortality in two contemporary US cohorts","volume":"29","author":"Huang","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.ypmed.2021.106504_bb0095","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/ije\/dyr116","article-title":"Cohort profile: the Irish longitudinal study on ageing","volume":"40","author":"Kearney","year":"2011","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.ypmed.2021.106504_bb0100","first-page":"3","article-title":"Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011\u20132012","author":"Mainous","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ypmed.2021.106504_bb0105","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2021.106504_bb0110","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/fampra\/cmz080","article-title":"A comparison of contemporary versus older studies of aspirin for primary prevention","volume":"37","author":"Moriarty","year":"2019","journal-title":"Fam. Pract."},{"key":"10.1016\/j.ypmed.2021.106504_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008656","article-title":"Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study","volume":"5","author":"Moriarty","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.ypmed.2021.106504_bb0120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00228-015-1815-1","article-title":"Longitudinal prevalence of potentially inappropriate medicines and potential prescribing omissions in a cohort of community-dwelling older people","volume":"71","author":"Moriarty","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ypmed.2021.106504_bb0125","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.sapharm.2018.08.014","article-title":"Deprescribing recommendations: an essential consideration for clinical guideline developers","volume":"15","author":"Moriarty","year":"2019","journal-title":"Res. Soc. Adm. Pharm."},{"key":"10.1016\/j.ypmed.2021.106504_bb0130","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.socscimed.2008.06.021","article-title":"Evaluating the impact of eligibility for free care on the use of general practitioner (GP) services: a difference-in-difference matching approach","volume":"67","author":"Nolan","year":"2008","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.ypmed.2021.106504_bb0135","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ypmed.2021.106504_bb0140","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0140-6736(19)30541-0","article-title":"The rise and fall of aspirin in the primary prevention of cardiovascular disease","volume":"393","author":"Raber","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2021.106504_bb0145","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jclinepi.2013.02.016","article-title":"Agreement between patient interview data on prescription medication use and pharmacy records in those aged older than 50 years varied by therapeutic group and reporting of indicated health conditions","volume":"66","author":"Richardson","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ypmed.2021.106504_bb0150","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/pds.3590","article-title":"The effect of free health care on polypharmacy: a comparison of propensity score methods and multivariable regression to account for confounding","volume":"23","author":"Richardson","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ypmed.2021.106504_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ypmed.2007.08.006","article-title":"Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland","volume":"46","author":"Rodondi","year":"2008","journal-title":"Prev. Med. (Baltim)."},{"key":"10.1016\/j.ypmed.2021.106504_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","author":"Rothwell","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.ypmed.2021.106504_bb0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/qshc.2005.016162","article-title":"Overprescribing of lipid lowering agents","volume":"15","author":"Smith","year":"2006","journal-title":"Qual. Saf. Heal. Care."},{"key":"10.1016\/j.ypmed.2021.106504_bb0170","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/CIRCULATIONAHA.117.028321","article-title":"Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish Nationwide, population-based cohort study","volume":"136","author":"Sundstr\u00f6m","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ypmed.2021.106504_bb0175","doi-asserted-by":"crossref","DOI":"10.5888\/pcd12.150342","article-title":"Aspirin use for the primary prevention of myocardial infarction among men in North Carolina, 2013","volume":"12","author":"Tchwenko","year":"2015","journal-title":"Prev. Chronic Dis."},{"key":"10.1016\/j.ypmed.2021.106504_bb0180","series-title":"A guide to deprescribing: Aspirin","author":"Tenni","year":"2019"},{"key":"10.1016\/j.ypmed.2021.106504_bb0185","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention","volume":"9","author":"Thun","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ypmed.2021.106504_bb0190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ypmed.2021.106504_bb0195","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/pds.2195","article-title":"Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy","volume":"21","author":"Wallach Kildemoes","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ypmed.2021.106504_bb0200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.amepre.2014.11.005","article-title":"Aspirin use among adults in the U.S.: results of a national survey","volume":"48","author":"Williams","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.ypmed.2021.106504_bb0205","article-title":"Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a National Retrospective Cohort Study","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ypmed.2021.106504_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112257","article-title":"Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan","volume":"9","author":"Wu","year":"2014","journal-title":"PLoS One"}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743521000888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743521000888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:07:04Z","timestamp":1777475224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743521000888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":42,"alternative-id":["S0091743521000888"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2021.106504","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.24.20161703","asserted-by":"object"}]},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin prescribing for cardiovascular disease in middle-aged and older adults in Ireland: Findings from The Irish Longitudinal Study on Ageing","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2021.106504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106504"}}